The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

European Journal of Cancer

Volumn 51, Issue 10, 2015, Pages 1321-1330

  Dirven, Linda ^a   Van Den Bent, Martin J ^b   Bottomley, Andrew ^c   Van Der Meer, Nelly ^b   Van Der Holt, Bronno ^b   Vos, Maaike J ^d   Walenkamp, Annemiek M E ^e   Beerepoot, Laurens V ^f   Hanse, Monique C J ^g   Reijneveld, Jaap C ^a,h   Otten, Aja ⁱ   De Vos, Filip Y F L ^j   Smits, Marion ^k   Bromberg, Jacoline E C ^b   Taal, Walter ^b   Taphoorn, Martin J B ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c EORTC DATA CENTER   (Belgium)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ ISALA HOSPITAL   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Bevacizumab; Brain tumour; Health related quality of life; Randomised controlled trial; Recurrent glioblastoma

Indexed keywords

BEVACIZUMAB; LOMUSTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; BRAIN NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL RATE; YOUNG ADULT;

EID: 84930216484     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.025     Document Type: Article

References (30)

1. D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, and J.Y. Delattre Primary brain tumours in adults Lancet 379 2012 1984 1996
2. R. Stupp, W.P. Mason, M.J. Van Den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. L. Dirven, N.K. Aaronson, J.J. Heimans, and M.J. Taphoorn Health-related quality of life in high-grade glioma patients Chin J Cancer 33 2014 40 45
4. A.A. Thomas, C.W. Brennan, L.M. Deangelis, and A.M. Omuro Emerging therapies for glioblastoma JAMA Neurol 71 2014 1437 1444
5. A. Woehrer, L. Bauchet, and J.S. Barnholtz-Sloan Glioblastoma survival: has it improved? Evidence from population-based studies Curr Opin Neurol 27 2014 666 674
6. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
7. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, and I. Stroud Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
8. J.J. Vredenburgh, A. Desjardins, J.E. Herndon, J. Marcello, D.A. Reardon, and J.A. Quinn Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
9. W. Taal, H.M. Oosterkamp, A.M. Walenkamp, H.J. Dubbink, L.V. Beerepoot, and M.C. Hanse Single-agent bevacizumab or lomustine versus A combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB Trial): a randomised controlled phase 2 trial Lancet Oncol 15 2014 943 953
10. P.Y. Wen, D.R. Macdonald, D.A. Reardon, T.F. Cloughesy, A.G. Sorensen, and E. Galanis Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
11. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, and N.J. Duez The European Organization for Research And Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
12. D. Osoba, N.K. Aaronson, M. Muller, K. Sneeuw, M.A. Hsu, and W.K. Yung The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires Qual Life Res 5 1996 139 150
13. M.J. Taphoorn, L. Claassens, N.K. Aaronson, C. Coens, M. Mauer, and D. Osoba An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients Eur J Cancer 46 2010 1033 1040
14. P.M. Fayers, N.K. Aaronson, K. Bjordal, M. Groenvold, D. Curran, and A. Bottomley The EORTC QLQ-C30 scoring manual 3rd ed. 2001 European Organization for Research and Treatment of Cancer Brussels
15. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
16. M. Calvert, J. Blazeby, D.G. Altman, D.A. Revicki, D. Moher, and M.D. Brundage Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension JAMA 309 2013 814 822
17. M.J. Taphoorn, R. Henriksson, A. Bottomley, T. Cloughesy, W. Wick, and W. Mason Health related quality of life (Hrqol) analyses in the AVAglio study, a randomized, placebo-controlled phase iii trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma Neurooncology (Meeting Abstracts) 15 Suppl. 3 2013 Iii232
18. M.J. Taphoorn, R. Stupp, C. Coens, D. Osoba, R. Kortmann, and M.J. Van Den Bent Health-related quality of life in patients with glioblastoma: a randomised controlled trial Lancet Oncol 6 2005 937 944
19. L.V. Van De Poll-Franse, F. Mols, C.M. Gundy, C.L. Creutzberg, R.A. Nout, and I.M. Verdonck-De Leeuw Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population Eur J Cancer 47 2011 667 675
20. O.L. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, and R. Nishikawa Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N Engl J Med 370 2014 709 722
21. M.R. Gilbert, J.J. Dignam, T.S. Armstrong, J.S. Wefel, D.T. Blumenthal, and M.A. Vogelbaum A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 2014 699 708
22. T.S. Armstrong, M. Won, J.S. Wefel, M.R. Gilbert, S. Pugh, and M.M. Wendland Comparative impact of tumor and treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825 Neurooncology (Meeting Abstracts) 15 Suppl. 3 2013 Iii226
23. J.S. Wefel, T. Cloughesy, J.L. Zazzali, M. Zheng, M. Prados, and P.Y. Wen Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab Neuro Oncol 13 2011 660 668
24. C.E. Schwartz, and M.A. Sprangers Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research Soc Sci Med 48 1999 1531 1548
25. R. Stupp, E.T. Wong, A.A. Kanner, D. Steinberg, H. Engelhard, and V. Heidecke NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality Eur J Cancer 48 2012 2192 2202
26. D. Osoba, M. Brada, M.D. Prados, and W.K. Yung Effect of disease burden on health-related quality of life in patients with malignant gliomas Neuro Oncol 2 2000 221 228
27. D. Osoba, M. Brada, W.K. Yung, and M. Prados Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme J Clin Oncol 18 2000 1481 1491
28. W.K. Yung, R.E. Albright, J. Olson, R. Fredericks, K. Fink, and M.D. Prados A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 2000 588 593
29. D. Vordermark Avoiding bias in the prospective evaluation of patients with brain metastases J Clin Oncol 25 2007 4023 4025
30. L. Dirven, J.C. Reijneveld, N.K. Aaronson, A. Bottomley, B.M. Uitdehaag, and M.J. Taphoorn Health-related quality of life in patients with brain tumors: limitations and additional outcome measures Curr Neurol Neurosci Rep 13 2013 359